Predictions have been made by an independent Commission on the Future of Surgery which was set up by the UK’s Royal College of Surgeons that a raft of state-of-the-art technology is going to transform the way medical surgery is carried out.
Q BioMed (OTCQB:QBIO), has been getting attention from biotech investors and pharma industry publications for its “upside down” biotech business model. The company expects to continue making strides in developing their product offerings and appears well positioned to generate revenue in 2019 and beyond.
Over the years, Investors have seen biotech companies as risky yet very profitable ventures. Mostly, this is due to the cutthroat competition where these companies have to come up with the best innovations in the healthcare department.
Shares of MacroGenics, Inc. (NASDAQ: MGNX) soared after the company announced positive results from SOPHIA, the Company’s Phase 3 clinical study of margetuximab in HER2-positive metastatic breast cancer patients.
An anticipated key FDA decision is set to transform Q BioMed (OTCMKTS: QBIO) from a biotech developer to a revenue generating manufacturer in what may be record time. That imminent event is already attracting interest from traders and investors, but a game changing plan revealed by the CEO may be an even stronger reason to focus on this emerging biotechnology accelerator.
Biopharmaceutical firm GW Pharmaceuticals PLC - ADR (NASDAQ:GWPH) has confirmed positive top line results from exploratory Phase 2a placebo-controlled clinical trial of Cannabidiol in 88 patients suffering from schizophrenia.